What is Chardan Capital's Estimate for CRSP FY2024 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at Chardan Capital increased their FY2024 EPS estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, November 6th. Chardan Capital analyst Y. Livshits now anticipates that the company will earn ($4.84) per share for the year, up from their prior forecast of ($5.75). Chardan Capital has a "Buy" rating and a $94.00 price target on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.23) per share. Chardan Capital also issued estimates for CRISPR Therapeutics' FY2025 earnings at ($4.62) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the previous year, the company posted ($1.41) earnings per share.

Several other research firms also recently weighed in on CRSP. Stifel Nicolaus cut their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Truist Financial decreased their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a report on Monday, August 12th. Barclays decreased their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of "Hold" and a consensus price target of $74.94.

CRISPR Therapeutics Price Performance

NASDAQ CRSP traded up $3.24 during trading hours on Monday, reaching $54.86. 3,656,415 shares of the company's stock traded hands, compared to its average volume of 1,465,855. The firm has a market cap of $4.68 billion, a PE ratio of -19.39 and a beta of 1.67. CRISPR Therapeutics has a 52-week low of $43.42 and a 52-week high of $91.10. The firm has a 50-day simple moving average of $47.60 and a 200 day simple moving average of $52.16.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company's stock, valued at $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company's stock, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $43,000. Advisors Asset Management Inc. increased its position in CRISPR Therapeutics by 3.7% during the 3rd quarter. Advisors Asset Management Inc. now owns 9,669 shares of the company's stock valued at $454,000 after buying an additional 342 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in CRISPR Therapeutics by 1.0% in the third quarter. Thrivent Financial for Lutherans now owns 47,696 shares of the company's stock valued at $2,241,000 after buying an additional 473 shares during the last quarter. Curi RMB Capital LLC boosted its holdings in CRISPR Therapeutics by 19.4% in the third quarter. Curi RMB Capital LLC now owns 46,715 shares of the company's stock worth $2,195,000 after acquiring an additional 7,597 shares in the last quarter. Finally, KBC Group NV increased its holdings in shares of CRISPR Therapeutics by 43.9% during the third quarter. KBC Group NV now owns 2,818 shares of the company's stock valued at $132,000 after acquiring an additional 860 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.